

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Disease models</b>			
Patient induced pluripotent stem (iPS) cell-derived cardiomyocytes as models for right ventricular dysplasia/cardiomyopathy	Cardiomyocytes generated from patient-derived iPS cells could help identify new treatments for right ventricular dysplasia/cardiomyopathy. Fibroblasts were isolated from an adult patient, reprogrammed into iPS cells and subsequently differentiated into cardiomyocytes. In culture, the resulting cells recapitulated an adult cardiomyocyte phenotype, showing exaggerated lipogenesis and deficiencies in calcium handling and greater apoptosis than control cells. Next steps include extending the findings to additional subtypes of right ventricular dysplasia/cardiomyopathy and using the patient-derived cells to evaluate therapeutic candidates.	Patents pending; licensing status undisclosed	Kim, C. <i>et al. Nature</i> ; published online Jan. 27, 2013; doi:10.1038/nature11799 <b>Contact:</b> Huei-Sheng Vincent Chen, Sanford-Burnham Medical Research Institute, La Jolla, Calif. e-mail: <a href="mailto:hsv_chen@burnham.org">hsv_chen@burnham.org</a>
	<b>SciBX 6(6); doi:10.1038/scibx.2013.151</b> Published online Feb. 14, 2013		